Quoin Pharmaceuticals, Ltd. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Quoin Pharmaceuticals, Ltd. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.80M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($8.96M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($8.69M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($9.38M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($21.46M) | Mar 15, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.80M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.60M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.31M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $2.67M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $1.56M | Mar 15, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.49M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.93M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.07M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $6.58M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $4.50M | Mar 15, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.54M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($7.86M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($7.86M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($8.48M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($5.72M) | Mar 15, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.39M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.71M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $12.17M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $14.46M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $9.36M | Mar 15, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.27M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.50M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.51M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $7.05M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $8.70M | Mar 15, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.12M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.20M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $5.66M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $7.41M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $657.0K | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($6.61M) | Mar 15, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($70.97M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($55.17M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($46.20M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($37.52M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($28.07M) | Mar 15, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.82M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.62M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.40M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $2.86M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $7.48M | Mar 15, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 52.44M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 8.95M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 987,220 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 403,887 | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 3.35B | Mar 15, 2023 |